single

Alembic Pharmaceuticals announced that the Company has receivedapproval from the US Food & Drug Administration (USFDA) for its Abbreviated NewDrug Application (ANDA) for Dorzolamide Hydrochloride Ophthalmic Solution USP,2%. The approved ANDA is therapeutically equivalent to the reference listed drugproduct (RLD) Trusopt Ophthalmic Solution, 2%, of Merck Sharp & Dohme Corp.Dorzolamide Hydrochloride Ophthalmic Solution is a carbonic anhydrase inhibitorindicated in the treatment of elevated intraocular pressure in patients with ocularhypertension or open-angle glaucoma.

Dorzolamide Hydrochloride Ophthalmic Solution USP, 2% has an estimated marketsize of US$ 35 million for twelve months ending December 2018 according to IQVIA

TAGS

0 thoughts on “Alembic Pharmaceuticals receives USFDA ANDA approval for Dorzolamide Hydrochloride Ophthalmic Solution”

Post Comment



  High Accuracy Stock Future Performance

Performance given here is genuine and can check by taking pay or call trial, no free trial given to anybody as our trial calls are also worth to earn money and check us, you can even check without trading in trial period.



Daily News

VIEW ALL
View My Stats